Targets for anti-metastatic drug development

Current Pharmaceutical Design

Volumn 19, Issue 28, 2013, Pages 5127-5134

  Stock, Anna Maria ^a   Troost, Gabriele ^a   Niggemann, Bernd ^a   Zänker, Kurt S ^a   Entschladen, Frank ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Cell migration; Chemokines; Cytokines; Invasion; Metastasis; Neurotransmitters

Indexed keywords

ANTIMETASTATIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHEMOKINE; CYTOKINE; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; NEUROTRANSMITTER; NORADRENALIN; PROPRANOLOL;

ARTICLE; CANCER CELL CULTURE; CANCER MORTALITY; CELL MIGRATION; CHEMOTAXIS; DRUG ACTIVITY; DRUG INDICATION; DRUG RESEARCH; DRUG TARGETING; HUMAN; METASTASIS; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; G-PROTEIN-COUPLED RECEPTOR KINASES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84881343238     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319280011     Document Type: Article

References (94)

1. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571-3.
2. Bastian P, Lang K, Niggemann B, Zaenker KS, Entschladen F. Myosin regulation in the migration of tumor cells and leukocytes within a three-dimensional collagen matrix. Cell Mol Life Sci 2005; 62: 65-76.
3. Palm D, Lang K, Brandt B, Zaenker KS, Entschladen F. In vitro and in vivo imaging of cell migration: two interdepending methods to unravel metastasis formation. Semin Cancer Biol 2005; 15: 396-404.
4. Entschladen F, Zanker KS, Powe DG. Heterotrimeric G protein signaling in cancer cells with regard to metastasis formation. Cell Cycle 2012; 10: 1086-91.
5. Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS. Neurotransmitters and chemokines regulate tumor cell migration: potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr Pharm Des 2005; 11: 403-11.
6. Kedrin D, van Rheenen J, Hernandez L, Condeelis J, Segall JE. Cell motility and cytoskeletal regulation in invasion and metastasis. J Mammary Gland Biol Neoplasia 2007; 12: 143-52.
7. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
8. Foord SM, Bonner TI, Neubig RR, et al. International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev 2005; 57: 279-88.
9. Lagerstrom MC, Schioth HB. Structural diversity of G proteincoupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008; 7: 339-57.
10. Kimple AJ, Bosch DE, Giguere PM, Siderovski DP. Regulators of G-protein signaling and their Galpha substrates: promises and challenges in their use as drug discovery targets. Pharmacol Rev 2011; 63: 728-49.
11. Tang XL, Wang Y, Li DL, Luo J, Liu MY. Orphan G proteincoupled receptors (GPCRs): biological functions and potential drug targets. Acta Pharmacol Sin 2012; 33: 363-71.
12. Yona S, Lin HH, Siu WO, Gordon S, Stacey M. Adhesion-GPCRs: emerging roles for novel receptors. Trends Biochem Sci 2008; 33: 491-500.
13. Gruber CW, Muttenthaler M, Freissmuth M. Ligand-based peptide design and combinatorial peptide libraries to target G proteincoupled receptors. Curr Pharm Des 2010; 16: 3071-88.
14. Chen L, Jin L, Zhou N. An update of novel screening methods for GPCR in drug discovery. Expert Opin Drug Discov 2012; 7: 791-806.
15. Lappano R, Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011; 10: 47-60.
16. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
17. Singh S, Singh UP, Grizzle WE, Lillard JW, Jr. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest 2004; 84: 1666-76.
18. Sasaki K, Natsugoe S, Ishigami S, et al. Expression of CXCL12 and its receptor CXCR4 correlates with lymph node metastasis in submucosal esophageal cancer. J Surg Oncol 2008; 97: 433-8.
19. Wagner PL, Hyjek E, Vazquez MF, et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg 2009; 137: 615-21.
20. Wang L, Wang L, Yang B, et al. Strong expression of chemokine receptor CXCR4 by renal cell carcinoma cells correlates with metastasis. Clin Exp Metastasis 2009; 26: 1049-54.
21. Murakami T, Kumakura S, Yamazaki T, et al. The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100. Antimicrob Agents Chemother 2009; 53: 2940-8.
22. Allavena P, Germano G, Marchesi F, Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res 2011; 317: 664-73.
23. Baba M, Takashima K, Miyake H, et al. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother 2005; 49: 4584-91.
24. Kang Y, Wu Z, Lau TC, et al. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cellmediated infection, and a resistant variant. J Biol Chem 2012; 287: 16499-509.
25. Nishikawa M, Takashima K, Nishi T, et al. Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5. Antimicrob Agents Chemother 2005; 49: 4708-15.
26. Takama Y, Miyagawa S, Yamamoto A, et al. Effects of a calcineurin inhibitor, FK506, and a CCR5/CXCR3 antagonist, TAK-779, in a rat small intestinal transplantation model. Transpl Immunol 2011; 25: 49-55.
27. Gladue RP, Brown MF, Zwillich SH. CCR1 antagonists: what have we learned from clinical trials. Curr Top Med Chem 2010; 10: 1268-77.
28. Xia M, Sui Z. Recent developments in CCR2 antagonists. Expert Opin Ther Pat 2009; 19: 295-303.
29. Walters MJ, Wang Y, Lai N, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2010; 335: 61-9.
30. Busch-Petersen J. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Curr Top Med Chem 2006; 6: 1345-52.
31. Singh S, Sadanandam A, Nannuru KC, et al. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res 2009; 15: 2380-6.
32. Varney ML, Singh S, Li A, Mayer-Ezell R, Bond R, Singh RK. Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Lett 2011; 300: 180-8.
33. Lang K, Niggemann B, Zanker KS, Entschladen F. Signal processing in migrating T24 human bladder carcinoma cells: role of the autocrine interleukin-8 loop. Int J Cancer 2002; 99: 673-80.
34. Strell C, Niggemann B, Voss MJ, Powe DG, Zanker KS, Entschladen F. Norepinephrine promotes the beta1-integrin-mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GROalpha release. Mol Cancer Res 2012; 10: 197-207.
35. Velasco-Velazquez M, Jiao X, De La Fuente M, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 2012; 72: 3839-50.
36. Kawada K, Sonoshita M, Sakashita H, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004; 64: 4010-7.
37. Nakamura ES, Koizumi K, Kobayashi M, et al. RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin Exp Metastasis 2006; 23: 9-18.
38. Airoldi I, Cocco C, Morandi F, Prigione I, Pistoia V. CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunol Immunother 2008; 57: 541-8.
39. Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS. Tumourcell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol 2004; 5: 254-8.
40. Powe DG, Entschladen F. Targeted therapies: Using beta-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol 2011; 8: 511-2.
41. Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001; 61: 2866-9.
42. Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 2003; 80: 63-70.
43. Lang K, Drell TL, Lindecke A, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004; 112: 231-8.
44. Palm D, Lang K, Niggemann B, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006; 118: 2744-9.
45. Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010; 70: 7042-52.
46. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 2011; 29: 2635-44.
47. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, et al. Betablocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011; 29: 2645-52.
48. Powe DG, Voss MJ, Zaenker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1: 628-38.
49. Grytli HH, Fagerland MW, Fossa SD, Tasken KA, Haheim LL. Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate 2013; 73: 250-60.
50. Diaz ES, Karlan BY, Li AJ. Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 2012; 127: 375-8.
51. De Giorgi V, Grazzini M, Gandini S, et al. Treatment with betablockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 2011; 171: 779-81.
52. Lemeshow S, Sorensen HT, Phillips G, et al. beta-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 2011; 20: 2273-9.
53. Guo K, Ma Q, Wang L, et al. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 2009; 22: 825-30.
54. Huang XY, Wang HC, Yuan Z, Huang J, Zheng Q. Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via beta-adrenergic receptor-dependent activation of P38/MAPK pathway. Hepatogastroenterology 2011; 59: 889-93.
55. Entschladen F, Drell TL, Lang K, et al. Analysis methods of human cell migration. Exp Cell Res 2005; 307: 418-26.
56. Meyer AS, Hughes-Alford SK, Kay JE, et al. 2D protrusion but not motility predicts growth factor-induced cancer cell migration in 3D collagen. J Cell Biol 2012; 197: 721-9.
57. Shah SM, Carey IM, Owen CG, Harris T, Dewilde S, Cook DG. Does beta-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 2011; 72: 157-61.
58. Niggemann B, Drell TL, Joseph J, et al. Tumor cell locomotion: differential dynamics of spontaneous and induced migration in a 3D collagen matrix. Exp Cell Res 2004; 298: 178-87.
59. Bastian P, Balcarek A, Altanis C, et al. The inhibitory effect of norepinephrine on the migration of ES-2 ovarian carcinoma cells involves a Rap1-dependent pathway. Cancer Lett 2009; 274: 218-24.
60. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
61. Powe DG, Voss MJ, Habashi HO, et al. Alpha-and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res Treat 2011; 130: 457-63.
62. Masur K, Lang K, Niggemann B, Zaenker KS, Entschladen F. High PKC-alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol Biol Cell 2001; 12: 1973-82.
63. Naylor TL, Tang H, Ratsch BA, et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. 2011; 71: 2643-53.
64. Li L, Miyamoto M, Ebihara Y, et al. DRD2/DARPP-32 expression correlates with lymph node metastasis and tumor progression in patients with esophageal squamous cell carcinoma. World J Surg 2006; 30: 1672-9; discussion 80-1.
65. Blaya B, Nicolau-Galmes F, Jangi SM, et al. Histamine and histamine receptor antagonists in cancer biology. Inflamm Allergy Drug Targets 2010; 9: 146-57.
66. Tilly BC, Tertoolen LG, Remorie R, et al. Histamine as a growth factor and chemoattractant for human carcinoma and melanoma cells: action through Ca2(+)-mobilizing H1 receptors. J Cell Biol 1990; 110: 1211-5.
67. Munoz M, Martinez-Armesto J, Covenas R. NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011. Expert Opin Ther Pat 2012; 22: 735-46.
68. Schuller HM, Al-Wadei HA, Majidi M. GABA B receptor is a novel drug target for pancreatic cancer. Cancer 2008; 112: 767-78.
69. Joseph J, Niggemann B, Zaenker KS, Entschladen F. The neurotransmitter gamma-aminobutyric acid is an inhibitory regulator for the migration of SW 480 colon carcinoma cells. Cancer Res 2002; 62: 6467-9.
70. Ortega A. A new role for GABA: inhibition of tumor cell migration. Trends Pharmacol Sci 2003; 24: 151-4.
71. Schuller HM. Beta-adrenergic signaling, a novel target for cancer therapy? Oncotarget 2010; 1: 466-9.
72. Grimaldi C, Pisanti S, Laezza C, et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 2006; 312: 363-73.
73. Joseph J, Niggemann B, Zaenker KS, Entschladen F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 2004; 53: 723-8.
74. Alpini G, Demorrow S. Changes in the endocannabinoid system may give insight into new and effective treatments for cancer. Vitam Horm 2009; 81: 469-85.
75. Zaenker KS, Entschladen F. Paving roads for new drugs in oncology. Recent Pat Anticancer Drug Discov 2009; 4: 137-45.
76. Festuccia C, Angelucci A, Gravina GL, et al. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost 2005; 93: 964-75.
77. Gauthier ML, Torretto C, Ly J, Francescutti V, O'Day DH. Protein kinase Calpha negatively regulates cell spreading and motility in MDA-MB-231 human breast cancer cells downstream of epidermal growth factor receptor. Biochem Biophys Res Commun 2003; 307: 839-46.
78. Price JT, Tiganis T, Agarwal A, Djakiew D, Thompson EW. Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase C-dependent mechanism. Cancer Res 1999; 59: 5475-8.
79. Palmieri D, Bronder JL, Herring JM, et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res 2007; 67: 4190-8.
80. Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008; 100: 1092-103.
81. Balkwill F, Mantovani A. Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 2010; 87: 401-6.
82. Savagner P. The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol 2010; 21 Suppl 7: vii89-92.
83. Gomes LR, Terra LF, Sogayar MC, Labriola L. Epithelialmesenchymal transition: implications in cancer progression and metastasis. Curr Pharm Biotechnol 2010; 12: 1881-90.
84. Heldin CH, Vanlandewijck M, Moustakas A. Regulation of EMT by TGFbeta in cancer. FEBS Lett 2012; 586: 1959-70.
85. Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol 2009; 5: 1145-68.
86. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15: 167-70.
87. Steeg PS. Angiogenesis inhibitors: motivators of metastasis? Nat Med 2003; 9: 822-3.
88. De Bock K, Mazzone M, Carmeliet P. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 2011; 8: 393-404.
89. Voss MJ, Moller MF, Powe DG, Niggemann B, Zanker KS, Entschladen F. Luminal and basal-like breast cancer cells show increased migration induced by hypoxia, mediated by an autocrine mechanism. BMC Cancer 2011; 11: 158.
90. Voss MJ, Niggemann B, Zanker KS, Entschladen F. Tumour reactions to hypoxia. Curr Mol Med 2010; 10: 381-6.
91. Jiang J, Tang YL, Liang XH. EMT: a new vision of hypoxia promoting cancer progression. Cancer Biol Ther 2011; 11: 714-23.
92. Li DM, Feng YM. Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets. Breast Cancer Res Treat 2011; 128: 7-21.
93. Drell TL, Zanker KS, Entschladen F. Translational research in oncology: the need of additional in vitro preclinical testing methods for new drugs. Curr Pharm Des 2012; 18: 3416-20.
94. Friedl P, Sahai E, Weiss S, Yamada KM. New dimensions in cell migration. Nat Rev Mol Cell Biol 2012; 13: 743-7.